Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03932331
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:29:07.256244+00:00
Published At
2025-03-20T00:00:00+00:00
Record Updated At
2026-04-20
Results Posted At
2025-03-20
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Phase I: Relapsed or Refractory B-cell Malignancies", "Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma", "Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-20"
protocolSection.identificationModule.nctId
"NCT03932331"
protocolSection.identificationModule.officialTitle
"A Phase 1/2 Open Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell Malignancies"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-03-20"

Study condition terms

  • Phase I: Relapsed or Refractory B-cell Malignancies (protocolSection.conditionsModule.conditions)
  • Phase II Cohort A: Relapsed or Refractory Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Phase II Cohort B: Relapsed or Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.